コンテンツへスキップ
Merck
  • [Asthma and Chlamydia pneumoniae. A future prospect for macrolides in general and roxithromycin in particular?].

[Asthma and Chlamydia pneumoniae. A future prospect for macrolides in general and roxithromycin in particular?].

Presse medicale (Paris, France : 1983) (1997-03-01)
C Mayaud
要旨

A LOGICAL HYPOTHESIS: Recent publications raise the question of an association between Chlamydia pneumoniae and asthma. There has been no formal proof justifying routine search for C.pneumoniae in patients with uncontrolled asthma nor for systematic treatment with an antibiotic. Can Chlamydia pneumoniae infection initiate or aggravate asthma? Are acute manifestations of asthma associated with an overly high frequency of recent C.pneumoniae infection? Is a past history of C.pneumoniae infection abnormally frequent in patients with chronic asthma? Rigorously controlled clinical trials evaluating the efficacy of antibiotics such as macrolides which are active against C.pneumoniae are warranted to further elucidate these questions.

材料
製品番号
ブランド
製品内容

ロキシトロマイシン, European Pharmacopoeia (EP) Reference Standard
システム適合性用ロキシスロマイシン, European Pharmacopoeia (EP) Reference Standard